NBTX (NBTX) Stock Price & Analysis
NBTX (NBTX) rose 0.15% to USD 39.7 as of July 26, 2026 at 09:46 UTC, according to Nexqual real-time market data.
NBTX last closed at USD 39.64; the session ranged USD 39.24–40.27 on volume of 103,693 shares. Market capitalization is $2.02B, with a 52-week range of USD 6.09–57.14 (NMS). Source: Nexqual, July 26, 2026 at 09:46 UTC.
Key Statistics (as of July 26, 2026 at 09:46 UTC)
| Price | USD 39.7 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 39.64 |
| Open | USD 40.26 |
| Day Range | USD 39.24 – 40.27 |
| 52-Week Range | USD 6.09 – 57.14 |
| Volume | 103,693 shares |
| Market Cap | $2.02B |
| Exchange | NMS |
Technical Analysis (NBTX)
Nexqual's technical model rates NBTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 09:46 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.53 (neutral) |
| vs SMA50 | Above (USD 39.2) |
| MACD | 0.44 (positive) |
Analyst Ratings (NBTX)
Wall Street analysts rate NBTX "Strong Buy" based on 3 analysts, with a mean price target of USD 44.36 (range USD 29.1–68.73), per Nexqual as of July 26, 2026 at 09:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 44.36 |
| High Target | USD 68.73 |
| Low Target | USD 29.1 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (NBTX)
Source: Nexqual, July 26, 2026 at 09:46 UTC.
Financials & Fundamentals (NBTX)
| Total Revenue | $32.59M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -196.42% |
| Profit Margin | -73.52% |
| Current Ratio | 1.09 |
| Total Cash | $52.75M |
| Total Debt | $95.32M |
| Free Cash Flow | $-7.89M |
Source: Nexqual, July 26, 2026 at 09:46 UTC.
Financial Health Score (NBTX)
Nexqual rates NBTX's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 09:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $53M cash vs $95M debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Mixed — No data |
Ownership (NBTX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +11.75% |
| Shares Outstanding | 50.79M |
| Float | 31.82M |
| Short % of Float | +0.23% |
Source: Nexqual, July 26, 2026 at 09:46 UTC.
Leadership (NBTX)
NBTX is led by Laurent Levy (age 52), Co-Founder, President of the Executive Board & CEO, per Nexqual as of July 26, 2026 at 09:46 UTC.
| Co-Founder, President of the Executive Board & CEO | Laurent Levy (age 52) |
|---|---|
| Chief Financial & Business Officer and Member of Executive Board | Bart Van Rhijn (age 51) |
| Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | Leonard A. Farber |
| Chief Product Innovation & Delivery Officer | Anne-Sophie Lariviere |
Major Backers & Investors (NBTX)
Notable institutional backers of NBTX include Johnson & Johnson, according to Nexqual as of July 26, 2026 at 09:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Johnson & Johnson | 11.11% |
Source: Nexqual, July 26, 2026 at 09:46 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 34.17 | ▼ 0.55% |
| IVA | Inventiva S.A. - American Depos | USD 4.46 | ▼ 1.76% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 10.07 | ▼ 8.12% |
| INBX | Inhibrx Biosciences, Inc. | USD 81.55 | ▼ 5.09% |
| OLMA | Olema Pharmaceuticals, Inc. | USD 11.7 | ▲ 1.83% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:46 UTC. This page is informational and not investment advice.